Don Haut, a life sciences executive and deal maker, has been appointed chief business officer by EG 427. With the appointment, the French biotech company is opening its US headquarters in Boston. Dr Haut has held senior positions in healthcare companies for over 20 years, most recently as chief executive officer at Carmine Therapeutics where he raised a Series A financing, and as chief business officer at Asklepios Biosciences where he was instrumental in its acquisition by Bayer.
Dr Haut will support EG 427’s transition to a clinical stage organisation with the filing of an investigational new drug (IND) application with the US Food and Drug Administration in early 2024 for EG110A to treat multiple severe bladder diseases. EG 427 is developing treatments in neurology from a non-replicative herpes simplex virus type 1 (nrHSV-1) based vector platform. Dr Haut holds a PhD in molecular microbiology and immunology from the University of Missouri Columbia and an MBA from Washington University’s Olin School of Business, both US.
EG 427 announced the appointment on December 14, 2023.
Copyright 2024 Evernow Publishing Ltd.